Calamos Wealth Management LLC Purchases Shares of 51,729 Teladoc Health, Inc. $TDOC

Calamos Wealth Management LLC acquired a new stake in Teladoc Health, Inc. (NYSE:TDOC) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 51,729 shares of the health services provider’s stock, valued at approximately $282,000.

Several other institutional investors also recently modified their holdings of TDOC. PNC Financial Services Group Inc. lifted its stake in Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 2,810 shares during the last quarter. IFP Advisors Inc raised its stake in Teladoc Health by 412.1% in the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after buying an additional 3,210 shares during the period. International Assets Investment Management LLC bought a new stake in Teladoc Health in the fourth quarter valued at approximately $45,000. Van ECK Associates Corp lifted its position in shares of Teladoc Health by 101.4% in the fourth quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock valued at $64,000 after buying an additional 4,607 shares during the last quarter. Finally, KBC Group NV lifted its position in shares of Teladoc Health by 88.3% in the fourth quarter. KBC Group NV now owns 9,632 shares of the health services provider’s stock valued at $67,000 after buying an additional 4,516 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health Trading Up 5.1%

Shares of NYSE:TDOC opened at $9.74 on Thursday. Teladoc Health, Inc. has a 12-month low of $4.40 and a 12-month high of $9.85. The business has a 50 day moving average of $7.71 and a 200-day moving average of $6.41. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. The stock has a market cap of $1.76 billion, a PE ratio of -10.05 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The firm had revenue of $613.85 million for the quarter, compared to the consensus estimate of $611.04 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.Teladoc Health’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.53) EPS. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. As a group, equities research analysts forecast that Teladoc Health, Inc. will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TDOC. Citigroup boosted their target price on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Tuesday, May 5th. Barclays reduced their price objective on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, March 26th. Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Bank of America increased their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.67.

Insider Transactions at Teladoc Health

In other news, insider Carlos Nueno sold 6,196 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the completion of the sale, the insider owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. The trade was a 9.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the transaction, the insider owned 110,261 shares in the company, valued at $841,291.43. This trade represents a 6.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 39,195 shares of company stock worth $299,058 over the last quarter. 0.70% of the stock is currently owned by corporate insiders.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.